Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Xentuzumab - Boehringer Ingelheim

Drug Profile

Xentuzumab - Boehringer Ingelheim

Alternative Names: BI-836845

Latest Information Update: 11 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Eli Lilly and Company
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Insulin-like growth factor I inhibitors; Insulin-like growth factor II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II HER2 negative breast cancer
  • Phase I/II Prostate cancer
  • No development reported Breast cancer; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 14 Jul 2023 Boehringer Ingelheim completes phase I trial in Solid tumours (late-stage disease) in Japan (NCT02145741)
  • 14 Jul 2023 Boehringer Ingelheim completes a phase I trial in Solid tumours in Japan (NCT02145741)
  • 01 Jun 2023 Boehringer Ingelheim completes a phase I trial in Prostate cancer (Combination therapy, Metastatic disease, Hormone refractory) in USA, the UK, Netherlands, Spain, Hong Kong, South Korea, Taiwan and Singapore (NCT02204072) (EudraCT2013-004011-41)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top